News
- Kindred Biosciences to Present at Bank of America Merrill Lynch Animal Health SummitFebruary 18, 2020 8:30 AM EST
- Kindred Biosciences Announces Half-Life Extension Technology for Canine AntibodiesJanuary 8, 2020 4:02 PM EST
- Kindred Biosciences Unveils Positive Results from Pilot Study of its Interleukin-4R Monoclonal Antibody Being Developed for the Treatment of Atopic Dermatitis in DogsDecember 16, 2019 8:02 AM EST
Events
- Monday, February 24, 2020 from 12:50 PM to 1:30 PM EST
- Wednesday, January 8, 2020 4:30 PM EST
- Thursday, November 21, 2019
|
||||||||||||||||
KindredBio proudly supports
Rabies Free Africa
Press Release
During this time, investors will have the opportunity to discuss recent developments, including the launch of KindredBio's first product, study results from key therapeutic programs in development, and upcoming milestones.
Conference Details:
Date:Tuesday, September 10, 2019
KindredBio participant: CEORichard Chin
Presentation time:8:20-8:45a.m. ET in Adams , 4th Fl
Location:Lotte New York Palace Hotel
Webcast URL: Click here
Date:Thursday, September 12, 2019
KindredBio participant: CEORichard Chin
Location: Parker New York
Date:Wednesday, October 2, 2019
KindredBio participant: President and COODenise Bevers
Presentation time: 9:30-10:00a.m ET in Track 5 -Empire Ballroom 2
Location: InterContinental New York Barclay
Webcast URL: Click here
An archived version of the above webcasts will be available for 30 days on the KindredBio website.
AboutKindred Biosciences
Kindred Biosciences is a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets. Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy. The company's strategy is to identify compounds and targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated compounds and targets for dogs, cats and horses. The company has a deep pipeline of novel drugs and biologics in development across many therapeutic classes. KindredBio's first approved drug is Mirataz® (mirtazapine transdermal ointment) for the management of weight loss in cats.
Important Safety Information
Mirataz® (mirtazapine transdermal ointment) is for topical use in cats only under veterinary supervision. Do not use in cats with a known hypersensitivity to mirtazapine or any of the excipients or in cats treated with monoamine oxidase inhibitors (MAOIs). Not for human use. Keep out of reach of children. Wear gloves to apply and wash hands after. Avoid contact with treated cat for 2 hours following application. The most common adverse reactions include application site reactions, behavioral abnormalities (vocalization and hyperactivity) and vomiting. Please see the full Prescribing Information.
Contact
Katja Buhrer
katja.buhrer@kindredbio.com
(917) 969-3438
SOURCEKindred Biosciences, Inc.